Evidence map›Paper›PMID 31415416›Full record

ArticleMedicine2019

Safety of Shujinjianyao pill in clinical real world: A prospective, observational, multicenter, large-sample study Protocol.

Xin Cui, Long Liang, Lianxin Wang, Zhifei Wang, Yuanyuan Li, Yang Gao, Cheng Zhang, Menghua Sun, Shiheng Wang, Jiani Liu and 4 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03598153 (A Registry Study of Shujinjianyao Pill Used in Clinical Real World), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 92% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03598153 unknown statusnot on this map

A Registry Study of Shujinjianyao Pill Used in Clinical Real World

Typeobservational_patient_registrySponsorChina Academy of Chinese Medical SciencesRan2018 to 2019Enrolled3,000ConditionsSciaticaArmsShujinjianyao Pill
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Xin CuiInstitute of Basic Research in Clinical Medicine.
Long LiangWangjing Hospital.
Lianxin WangInstitute of Basic Research in Clinical Medicine.
Zhifei WangInstitute of Basic Research in Clinical Medicine.
Yuanyuan LiInstitute of Basic Research in Clinical Medicine.
Yang GaoInstitute of Basic Research in Clinical Medicine.
Cheng ZhangInstitute of Basic Research in Clinical Medicine.
Menghua SunInstitute of Basic Research in Clinical Medicine.
Shiheng WangChina Institute for History of Medicine and Medical Literature.
Jiani LiuXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing.
Yue ZhangLonghua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zhibo WangXiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing.
Xu WeiWangjing Hospital.
Yanming XieInstitute of Basic Research in Clinical Medicine.
Institute of Physiology and Basic Medicine · RUChinese Academy of Medical Sciences & Peking Union Medical College · CNInstitute for History of Natural Sciences · CNShanghai University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLow back pain is a common health problem worldwide, which also is a leading cause of long-term disability and has an important effect on the global economy and society. Usually, conservative therapies are used to treat low back pain. As a kind of Chinese patent medicine, Shujinjianyao pill (SJJYP) has a great curative effect on low back pain. However, its safety has not been studied yet. Therefore, we carried out this clinical trial to observe the safety of SJJYP in the real world.

methodsFirst, participants need to meet the medication standards according to inclusion and exclusion criteria. Then, participants are conducted safety examination before taking SJJYP. After qualified screening, participants can be enrolled into the group. Second, all enrolled participants will receive SJJJYP for a period of 4 weeks. During the observation period, participants need to return to the hospital for a subsequent visit after 2 weeks of medication, and come to the hospital for safety check after 4 weeks of medication. Third, telephone follow-up is used to investigate any participants' physical discomfort after 6 to 8 weeks (2-4 weeks after medication withdrawal). After all these steps are completed, clinical observation is finished. If any adverse events occur during this process, we will record them in time. When serious adverse events occur, we will use nested case-control study to explore the causes and mechanisms. DISCUSSION: This study will obtain the safety results of SJJYP in clinical real world, which will offer a scientific basis for clinicians in the treatment of low back pain, and also provide a methodological basis for the safety study of other medicines.

trial registrationClinicalTrial.gov registration number is NCT03598153. This study was approved by the ethics committee of Wangjing hospital, China Academy of Chinese Medical Sciences (WJEC-KT-2018-012-P002).

Indexed as

Clinical Trials as TopicDrugs, Chinese HerbalHumansLow Back PainMulticenter Studies as TopicObservational Studies as TopicProspective StudiesResearch DesignDrugs, Chinese Herbal

Identifiers

PMID31415416
PMCPMC6831424
OpenAlexW2968470397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.